Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)
Status:
Recruiting
Trial end date:
2029-09-22
Target enrollment:
Participant gender:
Summary
This is an Italian, multicenter, randomized, open-label phase III trial which will evaluate
if Letrozole is superior to standard adjuvant chemotherapy in patients with hormone receptor
positive low-grade serous epithelial carcinoma of the ovary (LGSCO).
The hypothesis is that letrozole will significantly prolong median progression free survival
(PFS) compared with the standard chemotherapy treatment, namely carboplatin AUC 5 and
paclitaxel 175 mg/m2.
Phase:
Phase 3
Details
Lead Sponsor:
Ente Ospedaliero Ospedali Galliera
Collaborators:
Humanitas Hospital, Italy Istituto Di Ricerche Farmacologiche Mario Negri